Michael Ulz
Stock Analyst at Baird
(4.08)
# 569
Out of 4,944 analysts
104
Total ratings
50.82%
Success rate
13.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $42 → $25 | $4.39 | +469.48% | 7 | Aug 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $312 → $405 | $435.66 | -7.04% | 11 | Aug 1, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $55 → $62 | $42.67 | +45.30% | 5 | Jul 31, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $5.86 | +326.62% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $39.72 | +156.80% | 3 | Apr 24, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $3.42 | +485.65% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.59 | +1,288.01% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $11.05 | +162.44% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $8.52 | -17.84% | 7 | Mar 5, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $2.43 | +724.74% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.01 | +895.02% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $47.76 | +101.01% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $12.32 | +322.08% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $65.00 | -12.31% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $18.40 | +46.74% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.09 | +545.16% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $9.62 | +180.67% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.51 | +1,224.50% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.04 | +1,382.70% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.70 | +1,328.16% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.96 | +1.35% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $4.46 | +572.65% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.27 | +2,262.20% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $10.12 | +344.66% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $7.29 | +6,758.71% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $28.80 | +177.78% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $7.15 | +109.79% | 3 | Jul 12, 2017 |
Karyopharm Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $25
Current: $4.39
Upside: +469.48%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $312 → $405
Current: $435.66
Upside: -7.04%
Ionis Pharmaceuticals
Jul 31, 2025
Upgrades: Overweight
Price Target: $55 → $62
Current: $42.67
Upside: +45.30%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.86
Upside: +326.62%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $39.72
Upside: +156.80%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $3.42
Upside: +485.65%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.59
Upside: +1,288.01%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $11.05
Upside: +162.44%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $8.52
Upside: -17.84%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.43
Upside: +724.74%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.01
Upside: +895.02%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $47.76
Upside: +101.01%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $12.32
Upside: +322.08%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $65.00
Upside: -12.31%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $18.40
Upside: +46.74%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.09
Upside: +545.16%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $9.62
Upside: +180.67%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.51
Upside: +1,224.50%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.04
Upside: +1,382.70%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.70
Upside: +1,328.16%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.96
Upside: +1.35%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $4.46
Upside: +572.65%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.27
Upside: +2,262.20%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $10.12
Upside: +344.66%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $7.29
Upside: +6,758.71%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $28.80
Upside: +177.78%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $7.15
Upside: +109.79%